Novartis Investor Presentation
New Novartis: Our strategy
Our focus
> Core Therapeutic Areas
Technology platforms
Priority geographies
Capital allocation / structure
Our priorities
Conclusion
Abbreviations
Strong positioning in Cardiovascular, the leading cause
of death and disability
1. Core TAs - Cardiovascular
Phase 1
Phase 2
Phase 3 Registration
8
Novel approaches that aim to improve HF outcomes
Dyslipidemia treatments that improve CV
morbidity/mortality in identifiable high-risk groups
with high unmet need
Population health approach, initially with NHS.
agreement for broad and rapid access to Leqvio®
Chronic and acute renal specialty indications with
high unmet need and limited/no targeted therapies
Disease modifying therapies for
metabolic disorders
Selected compound (indication)
LeqvioⓇ (Hyperlipidemia)
LeqvioⓇ (CVRR-LDLC)
Leqvio® (Primary prevention)1
Pelacarsen (Lp(a))
XXB750 (Cardiovascular diseases)
Iptacopan (IgAN)
Iptacopan (C3G)
Disease area
Cardio
Renal
Iptacopan (IMN)
Iptacopan (Others)
TIN816 (S-AKI)²
Metabolic
MBL949 (Obesity)
Note: Bars in Gantt chart indicate current phase of development 1. Phase 3 not yet started 2. Phase 2 initiating
Novartis Investor Presentation | September 22, 2022
U
NOVARTIS | Reimagining MedicineView entire presentation